Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia

Boyer, Laurent; Richieri, Raphaëlle; Dassa, D.; Boucékine, Mohamed; Fernandez, Jessica; Vaillant, F.; Padovani, R.; Auquier, Pascal; Lançon, Christophe

doi:10.1016/j.psychres.2013.06.020

Cited by 49 publications

(35 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding of an increased risk of CAD in patients with MS (Table 5) is consistent with other reports [34,35]. MS has been reported to affect the clinical outcome of patients with schizophrenia not only because it is a direct complication, but also because it affects neurocognitive function in these patients [36] and quality of life in patients with psychosis [37]. Average BMI seemed to be higher in our patients than that reported for the general population [1,2].…”

Section: Discussionsupporting

confidence: 92%

The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute

Tseng¹,

Wang²,

Cheng³

et al. 2014

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

The prevalence rate of metabolic syndrome (MS) and coronary artery disease (CAD) has been found to be high in patients with chronic schizophrenia. Current evidence shows that CAD is underdiagnosed in this group. Our study evaluated the prevalence of MS and the risk of CAD in patients with chronic schizophrenia in a chronic care mental hospital in southern Taiwan. We included all patients with the diagnosis of schizophrenia or schizoaffective disorder. We collected all laboratory, physical examination, psychiatric interview, and chart review data. We also evaluated the risk of CAD in these patients using the Framingham point system. There was no significant age difference in the MS prevalence rate in these patients. The young patients with schizophrenia in our study tended to have a higher prevalence of MS than the general population. In addition, female patients had a higher prevalence rate of MS than males. Based on the Framingham point system, we found the 10-year risk of CAD to be higher among the patients with schizophrenia than in the general population. Our study highlights the importance of the high risk of MS in both younger and older patients with schizophrenia, without a significant relationship to the use of antipsychotics. More complete cohort studies are needed to confirm these findings. Psychiatrists may want to establish more specific and detailed clinical guidelines for patients with chronic schizophrenia with comorbid physical diseases, especially MS and CAD.

show abstract

Section: Discussionsupporting

confidence: 92%

The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute

Tseng¹,

Wang²,

Cheng³

et al. 2014

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…Previous reports indicated that obesity-related cardio-metabolic comorbidities (e.g., diabetes, hypertension, cardiovascular diseases) have been linked to cognitive decline in individuals with schizophrenia (Boyer et al, 2013). To address the potential impact of such cardio-metabolic comorbidities, we recorded the presence of cardio-metabolic comorbidities for each participant with schizophrenia.…”

Section: Resultsmentioning

confidence: 99%

“…To address the potential impact of such cardio-metabolic comorbidities, we recorded the presence of cardio-metabolic comorbidities for each participant with schizophrenia. Employing a strategy used by Boyer et al (2013), we created a continuous variable indexing the number of cardio-metabolic comorbidities criteria present. Accordingly, the number of cardio-metabolic comorbidities displayed a trend association with neurocognition (r=−0.28, p=0.08) and no significant relationship with AF or daily functioning.…”

Section: Resultsmentioning

confidence: 99%

“…Similarly, Friedman et al (Friedman et al, 2010) found that higher BMI and hypertension in individuals with schizophrenia were associated with poor immediate, delayed and recognition memory. In another recent report, the number of metabolic syndrome symptoms, a correlate of AF and BMI, were associated with neurocognitive impairments (Boyer et al, 2013). …”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning

Kimhy

Vakhrusheva

Bartels

et al. 2014

Psychiatry Research

View full text Add to dashboard Cite

Previous reports indicate that among healthy individuals low Aerobic Fitness (AF) and high Body-Mass Index (BMI) predict poor neurocognition and daily-functioning. It is unknown whether these associations extend to disorders characterized by poor neurocognition, such as schizophrenia. Therefore, we compared AF and BMI in individuals with schizophrenia and non-clinical controls, and then within the schizophrenia group we examined the links between AF, BMI, neurocognition and daily-functioning. Thirty-two individuals with schizophrenia and 64 gender- and age-matched controls completed assessments of AF (indexed by VO2max) and BMI. The former also completed measures of neurocognition, daily-functioning and physical activity. The schizophrenia group displayed significantly lower AF and higher BMI. In the schizophrenia group, AF was significantly correlated with overall neurocognition (r=0.57), along with executive functioning, working memory, social cognition, and processing speed. A hierarchical regression analysis indicated that AF accounted for 22% of the neurocognition variance. Furthermore, AF was significantly correlated with overall daily-functioning (r=0.46). In contrast, BMI displayed significant inverse correlations with neurocognition, but no associations to daily-functioning. AF was significantly correlated physical activity. The authors discuss the potential use of AF-enhancing interventions to improve neurocognitive and daily-functioning in schizophrenia, along with putative neurobiological mechanisms underlying these links, including Brain-Derived Neurotrophic Factor.

show abstract

“…Lindenmayer et al reported associations between MS diagnosis and cognitive impairment (i.e., worse processing speed, working memory, and problem‐solving). Boyer et al confirmed this and reported that worse memory, attention, and flexibility were associated with MS. Li et al also found an association between MS and impaired cognition in terms of lower attention, immediate and delayed memory scores. However, Meyer et al failed to show an association between MS and neurocognitive composite score, consisting of (working) memory, processing speed, vigilance, and reasoning.…”

Section: Introductionmentioning

confidence: 78%

Metabolic syndrome in schizophrenia patients associated with poor premorbid school performance in early adolescence

Nijs

Pet

2015

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia

Cited by 49 publications

References 44 publications

The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute

The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute

Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning

Metabolic syndrome in schizophrenia patients associated with poor premorbid school performance in early adolescence

Contact Info

Product

Resources

About